Evidence map›Paper›PMID 19445547›Full record

SynthesisPaediatric drugs2009

Current pharmacological management of gastro-esophageal reflux in children: an evidence-based systematic review.

Mark P Tighe, Nadeem A Afzal, Amanda Bevan, R Mark Beattie

Registry-linked trialAbstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Paediatric drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02907632 (Use of Metoclopramide for the Prevention of Gastroesophageal Reflux in Premature Infants Followed in an Outpatient Kangaroo Mother Care Clinic Before 40 Weeks of Gestational Age), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02907632 phase4completednot on this mapstarted 2017, after this paper: background citation

Use of Metoclopramide for the Prevention of Gastroesophageal Reflux in Premature Infants Followed in an Outpatient Kangaroo Mother Care Clinic Before 40 Weeks of Gestational Age: A Randomized Controlled Trial

TypeinterventionalSponsorNathalie CharpakRan2017 to 2019Enrolled490ConditionsGastroesophageal RefluxArmsMetoclopramide, Placebo
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pharmacological treatment of gastro-oesophageal reflux in children.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. A review of nonsurgical treatment for the symptom of irritability in infants with GERD.Journal for specialists in pediatric nursing : JSPN · 2012
    Pooled it
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Review
  9. A Critical Assessment of Extemporaneous Formulations for Proton Pump Inhibitors: The Importance of Proper Vehicle Selection.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022
    Article
  10. Review
  11. Compatibility of proton pump inhibitors in a preservative-free suspending vehicle.European journal of hospital pharmacy : science and practice · 2018
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Regurgitation in healthy and non healthy infants.Italian journal of pediatrics · 2009
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Mark P TighePaediatric Medical Unit, Southampton General Hospital, Southampton, UK.
Nadeem A Afzal
Amanda Bevan
R Mark Beattie
Southampton General Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastro-esophageal reflux (GER) is a common phenomenon, characterized by the regurgitation of the gastric contents into the esophagus. Gastro-esophageal reflux disease (GERD) is the term applied when GER is associated with sequelae or faltering growth. The main aims of treatment are to alleviate symptoms, promote normal growth, and prevent complications. Medical treatments for children include (i) altering the viscosity of the feeds with alginates; (ii) altering the gastric pH with antacids, histamine H(2) receptor antagonists, and proton pump inhibitors; and (iii) altering the motility of the gut with prokinetics, such as metoclopramide and domperidone. Our aim was to systematically review the evidence base for the medical treatment of gastro-oesophageal reflux in children. We searched PubMed, AdisOnline, MEDLINE, and EMBASE, and then manually searched reviews from the past 5 years using the key words 'gastro-esophageal' (or 'gastroesophageal'), 'reflux', 'esophagitis', and 'child$' (or 'infant') and 'drug$' or 'therapy'. Articles included were in English and had an abstract. We used the levels of evidence adopted by the Centre for Evidence-Based Medicine in Oxford to assess the studies for all reported outcomes that were meaningful to clinicians making decisions about treatment. This included the impact of clinical symptoms, pH study profile, and esophageal appearance at endoscopy. Five hundred and eight articles were reviewed, of which 56 papers were original, relevant clinical trials. These were assessed further. Many of the studies considered had significant methodological flaws, although based on available evidence the following statements can be made. For infant GERD, ranitidine and omeprazole and probably lansoprazole are safe and effective medications, which promote symptomatic relief, and endoscopic and histological healing of esophagitis. Gaviscon(R) Infant sachets are safe and can improve symptoms of reflux. There is less evidence to support the use of domperidone or metoclopramide. More evidence is needed before other anti-reflux medications can be recommended. For older children, acid suppression is the mainstay of treatment. The largest evidence base supports the early use of H(2) receptor antagonists or proton pump inhibitors.

Indexed as

AntacidsAnti-Ulcer AgentsChildChild, PreschoolDopamine AntagonistsEvidence-Based MedicineGastroesophageal RefluxHistamine H2 AntagonistsHumansInfantProton Pump InhibitorsAntacidsAnti-Ulcer AgentsDopamine AntagonistsHistamine H2 AntagonistsProton Pump Inhibitors

Identifiers

PMID19445547
OpenAlexW18630047

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.